<?xml version="1.0" encoding="UTF-8"?>
<ref id="B80-vaccines-07-00070">
 <label>80.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Ishida</surname>
    <given-names>J.H.</given-names>
   </name>
   <name>
    <surname>Patel</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Mehta</surname>
    <given-names>A.K.</given-names>
   </name>
   <name>
    <surname>Gatault</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>McBride</surname>
    <given-names>J.M.</given-names>
   </name>
   <name>
    <surname>Burgess</surname>
    <given-names>T.</given-names>
   </name>
   <name>
    <surname>Derby</surname>
    <given-names>M.A.</given-names>
   </name>
   <name>
    <surname>Snydman</surname>
    <given-names>D.R.</given-names>
   </name>
   <name>
    <surname>Emu</surname>
    <given-names>B.</given-names>
   </name>
   <name>
    <surname>Feierbach</surname>
    <given-names>B.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Phase 2 randomized, double-blind, placebo-controlled trial of RG7667, a combination monoclonal antibody, for prevention of cytomegalovirus infection in high-risk kidney transplant recipients. Antimicrob</article-title>
  <source>Agents Chemother.</source>
  <year>2017</year>
  <volume>61</volume>
  <fpage>e01794-16</fpage>
  <pub-id pub-id-type="doi">10.1128/AAC.01794-16</pub-id>
 </element-citation>
</ref>
